SNY Q2 Earnings: 3 Pipeline Cuts, Dupixent €5.2B

Sanofi reported Q2 2026 earnings on July 30 that beat on every line. Sales hit €11.6 billion, up 17.8% at constant exchange rates. Business EPS climbed 33.3% to €2.09. The company upgraded 2026 guidance to roughly 10% sales growth. By any conventional measure, this was a blowout quarter.

The stock dropped 5.8% from $45.54 on July 28 to $42.89 on earnings day. Volume more than tripled to 10.2 million shares from 3.5 million the prior session. Investors were not selling the results. They were selling the €1 billion in pipeline write-offs that came with them.

Three Cuts, One Quarter, One Pattern

CEO Belén Garijo, in her first earnings call since taking the role in late April, used the word “transformation” repeatedly. The financial cost of that transformation became clear in the fine print. Sanofi discontinued two more programs on top of the amlitelimab cut already announced on July 24. Three immunology assets axed in a single quarter. The combined impairment charges exceeded €1 billion.

The first cut was itpekimab, an anti-IL-33 monoclonal antibody co-developed with Regeneron for COPD and chronic rhinosinusitis with nasal polyps. The AERIFY Phase 3 program was a split decision: AERIFY-1 (NCT04701983) met its primary endpoint with a 27% reduction in moderate-to-severe COPD exacerbations at Week 52 in former smokers. AERIFY-2 (NCT04751487) did not, showing just a 2% reduction at Week 52 for the every-two-weeks dose despite an 18% benefit at Week 24. The efficacy faded between Week 24 and Week 52 in the second trial. Regeneron’s George Yancopoulos called the results something that “merit further exploration” in the May 2025 press release. Fifteen months later, exploration is over. Sanofi pulled the plug.

The second cut was balinatunfib, an oral small-molecule TNF inhibitor (SAR441566) being developed for Crohn’s disease and ulcerative colitis. This drug had already failed its Phase 2 psoriasis primary endpoint (PASI-75) earlier. Sanofi refocused the program on inflammatory bowel disease, but the earnings release confirmed the Crohn’s and UC programs are now discontinued too. An oral TNF inhibitor would have been a meaningful drug if it worked, since injectable TNF blockers like Humira and Remicade generated over $30 billion in peak sales across their life cycles. But “would have been” is the operative phrase. The molecule could not clear a Phase 2 bar in psoriasis, and the IBD pivot did not save it.

The Dupixent Juggernaut

The reason the pipeline cuts matter less than they appear is that Sanofi’s revenue engine is running at a pace that absorbs the write-offs. Dupixent sales reached €5.2 billion in Q2, up 37.6%, crossing €5 billion in a single quarter for the first time. Sanofi raised its 2030 Dupixent sales target to approximately €25 billion at constant exchange rates.

Dupixent was approved in COPD in the US in April 2025 as the first biologic for the disease. That label expansion alone opens a market of roughly 16 million COPD patients in the US and EU. The drug is now approved across atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and COPD. Each new indication adds roughly €2 to €4 billion in peak revenue potential.

The irony is that itepekimab was supposed to be the next Dupixent. Both drugs target inflammatory pathways relevant to COPD. Dupixent blocks IL-4 and IL-13. Itepekimab blocked IL-33. The difference is that Dupixent’s Phase 3 data was consistent across two registrational trials, while itepekimab’s was not. One positive trial is not enough for a regulatory filing in COPD, and Sanofi decided not to gamble on a second program that already showed a fading effect.

The Regeneron Question

The itpepekimab cut has a dimension the other two do not: the Regeneron partnership. Itepekimab was co-developed under the same collaboration agreement that produced Dupixent. Garijo told analysts she wants to “rebuild trust” with Regeneron and expand the collaboration. That language is revealing. Regeneron sued Sanofi in November 2024 alleging that Sanofi stonewalled access to pharmacy benefit manager contracts that determine Dupixent rebates. Since Regeneron splits Dupixent profits with Sanofi in the US, opaque rebate accounting directly impacts Regeneron’s revenue.

The litigation is in early stages. But the fact that the new CEO publicly acknowledged trust problems on her first earnings call tells you the relationship was strained under the prior regime. Garijo’s framing was that she wants to be “transparent” and identify “opportunities to work better together.” Whether that translates into a restructured partnership, a settlement, or simply better communication remains unclear. For investors, the key risk is that a Dupixent partnership dispute could complicate the commercialization of future label expansions, which are the primary revenue growth driver through 2030.

The Valuation Gap Is Real and Earned

Sanofi trades at $43.08 with a market cap of $102.8 billion. The stock is down 3.6% year to date against a pharma industry average gain of 16.9%. The P/S ratio sits at approximately 1.9x trailing twelve-month sales. Compare that to the peer group:

• AstraZeneca (AZN): P/S 4.35x, market cap roughly $262B
• AbbVie (ABBV): P/S 7.23x, market cap roughly $455B
• GSK: P/S 2.39x, market cap roughly $80B

Sanofi trades at less than half AstraZeneca’s multiple and roughly a quarter of AbbVie’s. GSK’s Q2 earnings showed that even a pharma company facing patent cliffs and pipeline gaps can command a higher revenue multiple than Sanofi if investors trust the R&D engine. AbbVie’s Q2 demonstrated the opposite: a premium multiple survives when a company successfully transitions from a $20B-revenue Humira to a successor portfolio.

The market is pricing Sanofi as a Dupixent dependency story with a broken pipeline behind it. That is not entirely wrong. Dupixent is 45% of Q2 net sales. The composition-of-matter patent expires in the US in October 2027 with a patent term extension to March 2031. Sanofi says it has a “vigorous defense planned” to extend exclusivity beyond that date, but biosimilar entrants will eventually erode the franchise. Without a credible late-stage immunology successor, the post-2031 revenue cliff is the structural reason the multiple stays compressed.

The pharma launches portfolio is the counter-argument. ALTUVIIIO (hemophilia A) posted €349 million in Q2 sales, up 23.7%. Ayvakit (systemic mastocytosis, acquired in the Blueprint Medicines deal) contributed €190 million. Sarclisa added €187 million, up 35.7%, with an on-body injector approval expanding its differentiation. The combined launches portfolio generated €1.3 billion in Q2, up 48.3%, and Sanofi targets €10 billion from this group by 2030. If that trajectory holds, the launches portfolio alone replaces roughly 40% of current Dupixent revenue.

The Venglustat Litmus Test

The next binary catalyst for Sanofi is venglustat, with a PDUFA date of November 25 for GD3 gangliosidosis. This is a small rare disease indication with peak sales estimates of $50 to $150 million, less than 0.3% of Sanofi’s revenue base. The approval is likely given the Phase 3 data, but the stock impact will be zero. At $102.8 billion market cap, a $100 million drug does not move the needle.

The real test is whether Garijo’s pipeline prioritization produces a credible late-stage asset that can succeed Dupixent. Three immunology programs were cut this quarter. The question is what replaces them. Garijo said she will “intensify” business development and M&A activity, but no deal has been announced. The €1 billion share buyback is complete, freeing capital. But capital without a target is not a strategy.

Risks

The primary risk is not the pipeline cuts. Those are backward-looking charges for decisions that were already made. The risk is that the R&D productivity problem that produced three failed immunology assets in one quarter is structural, not transitional. If Garijo’s “accelerated transformation roadmap” produces more write-offs than new filings over the next 12 months, the multiple compresses further.

The secondary risk is the Regeneron relationship. A partnership dispute that escalates beyond the current litigation into delayed label expansion filings or renegotiated economics would directly threaten the €25 billion 2030 Dupixent target. Investors should monitor whether Garijo’s “rebuild trust” language converts into a concrete settlement or expanded collaboration agreement by Q3 or Q4.

The third risk is the 2031 patent cliff. Sanofi’s patent defense strategy is real but unproven. Biosimilar entrants for Dupixent are already in development. The window between now and 2031 is the time to build the post-Dupixent revenue base, and three pipeline cuts in one quarter consumed time that was already scarce.

Verdict

Sanofi at $43 and 1.9x sales is cheap for a reason. The reason is that the market does not believe the pipeline can replace Dupixent before biosimilars arrive. Three immunology failures in one quarter reinforced that skepticism. The stock’s 5.8% drop on a beat-and-raise quarter tells you the market is pricing R&D credibility, not quarterly results.

The case against buying SNY here is straightforward. Dupixent grew 37.6% to €5.2B in a single quarter and the launches portfolio is growing fast, but the pipeline credibility gap is not closeable with a single earnings call and a new CEO. Garijo needs to show a deal or a Phase 3 initiation in immunology before the multiple re-rates. If she delivers a credible acquisition or a new Phase 3 program by Q4 2026, the stock re-rates toward GSK’s 2.4x multiple, which implies roughly 25% upside from current levels. If the next two quarters produce more write-offs than new filings, the stock tests the low $30s.

The risk-reward is asymmetric but not in a good way. The upside requires evidence that does not yet exist. The downside is a continuation of the pattern already in motion. Hold. Watch for a BD deal or a Phase 3 initiation before adding. The BMY Q2 earnings analysis showed that a working Growth Portfolio transition can justify a Hold at a discount multiple. Sanofi has not proven its transition yet.